Skip to content

EyePoint, Inc. EYPT Return on equity

Return on equity at other companies

Merck & Co. logo
Merck & Co.MRK
19%-20.3pp
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
14.5%-1.4pp
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-68.6%+17.0pp
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-208.8%+2,306pp
HRO
HarrowHROW
-50%+17.5pp
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-325.6%+36.9pp

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+189%
Enterprise value$1.15B+228%
P/S158.5×+151×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Calculated from EyePoint, Inc. ’s reported figures.

Based on trailing twelve months.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's return on equity?
EyePoint, Inc. (EYPT) reported return on equity of -102.7% in Q1 2026.
How has EyePoint, Inc. 's return on equity changed year-over-year?
EyePoint, Inc. 's return on equity decreased by 91.8% year-over-year, from -53.5% to -102.7%.
What is the long-term trend for EyePoint, Inc. 's return on equity?
Over 5 years (2020 to 2025), EyePoint, Inc. 's return on equity has grown at a -26.6% compound annual growth rate (CAGR), from -337.9% to -72.2%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.